Table 1 Association between PSMD6 rs831571 and clinical features in the rosiglitazone cohort.

From: A variant of PSMD6 is associated with the therapeutic efficacy of oral antidiabetic drugs in Chinese type 2 diabetes patients

Parameter

 

CC

CT

TT

P value

Age(year)

 

50.69 ±1.18

52.91 ±1.52

53.50 ±3.24

0.5793

Gender(male/female)

 

27/8

30/17

7/3

0.3617

Dosage(mg/day)

 

5±0.31

5.87±0.29

5.33±0.67

0.1428

BMI(kg/m2)

Baseline

25.03±0.56

24.08±0.45

24.45±0.90

0.8998

 

24weeks

24.87±0.69

24.87±0.45

25.56±1.14

0.0309

 

48weeks

24.77±0.70

24.98±0.47

24.77±1.00

0.2262

 

Δ24weeks

–0.38±0.23

0.005±0.18

0.84±0.87

0.0956

 

Δ48weeks

–0.29±0.26

0.08±0.20

0.06±0.17

0.2211

Fasting glucose(mmol/l)

Baseline

8.80±0.30

9.02±0.27

9.63±0.47

0.2381

 

24weeks

6.14±0.19

6.65±0.16

6.74±0.25

0.0368

 

48weeks

6.47±0.21

6.60±0.19

6.97±0.46

0.4322

 

Δ24weeks

–2.63±0.37

–2.38±0.29

–2.96±0.44

0.2826

 

Δ48weeks

–2.32±0.33

–2.42±0.32

–3.13±0.49

0.3221

2-h glucose(mmol/l)

Baseline

13.74±0.56

12.84±0.43

14.54±0.95

0.9416

 

24weeks

7.73±0.45

8.84±0.39

8.87±0.63

0.0468

 

48weeks

9.02±0.48

8.81±0.33

8.84±0.54

0.9191

 

Δ24weeks

–6.17±0.66

–3.99±0.56

–5.90±1.17

0.0364

 

Δ48weeks

–4.54±0.78

–4.04±0.50

–5.60±1.37

0.1793

Glycated hemoglobin (%)

Baseline

8.54±0.26

8.24±0.24

7.96±0.32

0.7197

 

24weeks

6.18±0.13

6.59±0.10

6.36±0.17

0.0233

 

48weeks

6.23±0.15

6.52±0.13

6.19±0.11

0.1179

 

Δ24weeks

–2.35±0.26

–1.65±0.24

–1.62±0.30

0.0247

 

Δ48weeks

–2.25±0.25

–1.54±0.28

–1.79±0.42

0.0460

Fasting insulin (mU/l)

Baseline

14.15±0.18

15.06±1.18

13.88±1.94

0.9019

 

24weeks

16.97±1.67

15.19±1.20

16.95±2.75

0.6440

 

48weeks

16.26±1.90

14.90±0.97

22.57±5.10

0.5036

 

Δ24weeks

2.51±1.75

0.13±1.34

2.28±2.22

0.7341

 

Δ48weeks

1.85±1.61

–0.36±1.35

8.70±5.04

0.1299

HOMA-IR

Baseline

5.43±0.42

6.02±0.49

6.01±0.92

0.7522

 

24weeks

4.88±0.62

4.44±0.35

5.14±0.90

0.7319

 

48weeks

4.82±0.77

5.50±0.38

6.30±1.52

0.7580

 

Δ24weeks

–0.66±0.67

–1.58±0.51

–1.26±0.66

0.9670

 

Δ48weeks

–0.73±0.65

–1.67±0.55

–0.69±0.97

0.5336

HOMA-B

Baseline

61.29±6.32

60.58±6.29

47.71±7.79

0.7316

 

24weeks

134.18±9.97

117.53±16.9

106.88±17.0

0.0561

 

48weeks

122.55±11.02

108.71±9.14

110.46±15.20

0.4806

 

Δ24weeks

71.08±11.08

56.94±16.94

56.26±16.89

0.0547

 

Δ48weeks

59.92±11.08

46.54±10.12

60.99±12.52

0.3521

Acute insulin response(mU/l)

Baseline

30.28±4.25

32.17±4.08

33.97±3.78

0.4667

 

24weeks

27.93±3.90

27.11±2.99

36.04±11.05

0.7830

 

48weeks

34.83±5.82

26.53±3.03

36.31±10.28

0.5986

 

Δ24weeks

–2.35±3.84

–5.06±3.62

0.91±8.66

0.9454

 

Δ48weeks

5.06±5.38

–6.05±4.51

2.34±9.27

0.2180

  1. Note: Data are shown as means ± SEM. P values <0.05 are shown in bold. Δ value = T24 or 48 weeks value - baseline (T0) value. P values were adjusted for age, gender and BMI at baseline when linear regression model was adopted.
  2. HOMA-B, homeostasis model assessment of β-cell function; HOMA-IR, homeostasis model assessment of insulin resistance.
Back to article page